Blood reimbursement
This article was originally published in The Gray Sheet
Executive Summary
CMS should accept industry data to "remedy the inadequacies of blood reimbursement quickly in order to avert the development of issues with blood safety and availability," AdvaMed, the American Hospital Association, American Red Cross and the American Association of Blood Banks state in a 1July 28 letter. The groups jointly submitted a 2letter to Bureau of Labor Statistics Commissioner Kathleen Utgoff, PhD, seeking a meeting to urge development of a blood producer price index - the group's long-term goal to improving reimbursement (3"The Gray Sheet" July 12, 2004, p. 10)...
You may also be interested in...
CMS Takes Steps To Improve Blood Product Rates Under OPPS Proposed Rule
AdvaMed is cautiously optimistic about CMS' plan to create ambulatory payment classifications (APCs) for blood and blood products in the outpatient setting, but views the impatient setting as the larger battle in achieving improved reimbursement
Blood Banks, AdvaMed Collaborate To Improve Blood Product Payments
Various health industry organizations plan to compile data on the actual costs of blood in order to improve product reimbursement
New EU Filings
Obecabtagene autoleucel, Autolus Therapeutics’s investigational treatment for relapsed or refractory B cell precursor acute lymphoblastic leukemia, is among the latest products that have been filed for review by the European Medicines Agency for potential EU marketing approval.